This study is a randomized, triple-blind, placebo-controlled, interventional trial aiming to elucidate the impact of rifaximin-induced gut microbiota alteration to the psychobiological functioning of healthy men. The intervention will be performed in a parallel group design where one group will receive rifaximin (Targaxan 550 mg) twice daily for two weeks (treatment arm), while the other group will receive placebo (placebo arm).~Primary objective: to test the effect of rifaximin on stress sensitivity and fear-related processes~Secondary objective: to determine the mediating and/or moderating factors that underlie rifaximin-induced psychobiological changes
A randomized, triple-blind, placebo-controlled study on the effect of rifaximin on psychobiological functions in healthy men.